Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)

NCTNCT07496463Other id2026P000332

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Enrolling by invitation
Phase: Phase 2
Enrollment: 1 participants (estimated)
Sponsor: Massachusetts General Hospital · Other
Design: Allocation not applicable · Open label (no masking)
Countries: 1 country
United States
Start: 21 Jul 2026
Primary completion: 30 Apr 2027 (estimated)
Completion: 30 Apr 2027 (estimated)
First posted: 27 Mar 2026
Last update posted: 23 Jul 2026
Conditions: Pseudohypoparathyroidism Type 1a · Obesity

Timeline

1 trial · 1 ongoing

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

202620272028

Ph 2
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
NCT07496463
21 Jul 2026 to est. 30 Apr 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.

Interventions

SetmelanotideDrug

Arms1

Other
Patient with pseudohypoparathyroidism type 1a
A preselected patient with obesity related to pseudohypoparathyroidism type 1a.

Primary outcomes1

Outcomes the sponsor listed as primary.

Greater than or Equal to 5% Weight loss
Time frame · Baseline to 6 Months
Registry description
Greater than or equal to 5% weight loss from baseline

Secondary outcomes(4)

Percent Weight Loss
Time frame · Baseline to 3 Months, Baseline to 6 Months
Registry description
Percent change in weight from baseline
Trunk Fat Mass
Time frame · Baseline to 6 Months
Registry description
Trunk fat mass measured on dual-energy x-ray absorptiometry scan
Hemoglobin A1c
Time frame · Baseline to 3 Months, Baseline to 6 Months
Registry description
Hemoglobin A1c (%) measured on blood draw
Serum Triglycerides
Time frame · Baseline to 3 Months, Baseline to 6 Months
Registry description
Serum triglycerides (mg/dL) measured on blood draw

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex: All
Age: Not stated
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Known patient with PHP1a (confirmed GNAS mutation) * Optimized therapy for diabetes and dyslipidemia Exclusion Criteria: \- Use of medications that may affect endpoints that are changed within 3 months prior to Baseline or that are likely to require a change in dose during the open-label treatment period

PepBank is a research reference. Talk to a doctor before you use any peptide.